ライフサイエンスコーパス: Clostridium

1 onventional methods: Bacteroides spp. (30%), Clostridium (11%), and Fusobacterium spp. (8%).

2 ular complexes between CdSe nanocrystals and Clostridium acetobutylicum [FeFe] hydrogenase I (CaI) en

3 Clostridium acetobutylicum has received renewed interest

4 olyketides native to the anaerobic bacterium Clostridium acetobutylicum, an organism well-known for i

5 ociated with increases in Coriobacteriaceae, Clostridium and Lactobacillus.

6 Anaerobic bacteria, such as Clostridium and Salmonella, can selectively invade and c

7 naerobacter, Paraclostridium, Haloimpatiens, Clostridium, and Bacillus were dominating in the bioreac

8 taxonomies Akkermansia, Christensenellaceae, Clostridium, and Odoribacter in Ldlr(-/-)( Casp1(-/-)) m

9 uous cultures of the gas-fermenting acetogen Clostridium autoethanogenum Online gas analysis and high

10 From 1976 to 2016, neurotoxigenic Clostridium baratii type F caused 18 (<0.5%) reported US

11 Recently, an [FeFe] hydrogenase from Clostridium beijerinckii (CbHydA1) was reported to regai

12 in dehydrogenase/reductase, respectively, in Clostridium beijerinckii NCIMB 8052 (Cb), resulting in t

13 um cluster XIVa species Blautia producta and Clostridium bolteae restores colonization resistance aga

14 eae; revisions within the Propionibacterium, Clostridium, Borrelia, and Enterobacter genera; and a ma

15 ial protein, transcription terminator Rho of Clostridium botulinum (Cb-Rho), could form a prion.

16 Laboratory testing was performed for Clostridium botulinum and botulinum neurotoxin.

17 The natural Clostridium botulinum C2 toxin was then delivered to hum

18 Clostridium botulinum isolates from 4 patients were clos

19 BAcTrace is based on Clostridium botulinum neurotoxin A, Botox, which we engi

20 actin-like ParM is encoded on the large pCBH Clostridium botulinum plasmid.

21 linum neurotoxins, produced by the bacterium Clostridium botulinum, act on their hosts by a high-affi

22 kholderia mallei, Burkholderia pseudomallei, Clostridium botulinum, Brucella melitensis, Brucella abo

23 hewanella oneidensis, Shewanella woodyi, and Clostridium botulinum, indicating that the binding site

24 mechanisms, we characterized the enzyme from Clostridium botulinum, which belongs to a subclass of cl

25 toxins (BoNTs) are a product of the bacteria Clostridium botulinum.

26 g mouse bioassay for BoNT and/or culture for Clostridium botulinum.

27 he mouse gut, including members of the genus Clostridium, but no AI-2 receptor had been identified in

28 describe two pAgos from mesophilic bacteria, Clostridium butyricum (CbAgo) and Limnothrix rosea (LrAg

29 ivity of a bacterial Argonaute nuclease from Clostridium butyricum (CbAgo) in vivo.

30 ll-characterized butyrate-producing bacteria Clostridium butyricum CGMCC0313.1 (CB0313.1) on hypergly

31 uppressing the beneficial butyrate-producing Clostridium butyricum.

32 elineation and metabolite turnover rates) of Clostridium carboxidivorans P7, a model strain for indus

33 ize CcCas9, a Type II-C CRISPR nuclease from Clostridium cellulolyticum H10.

34 ification tests (NAATs) for the diagnosis of Clostridium (Clostridioides) difficile infection (CDI) l

35 Clostridium (Clostridioides) difficile is a Gram positiv

36 stinal discomfort, inversely associated with Clostridium cluster IV and Ruminococcus callidus, was im

37 vealed higher 3-IS levels (P < .001), higher Clostridium cluster XIVa (CCXIVa) abundance (P = .004),

38 sortium of commensal bacteria containing the Clostridium cluster XIVa species Blautia producta and Cl

39 sis characterized by increased proportion of Clostridium coccoides (cluster XIVa), C coccoides-Eubact

40 relative abundance of the same single genus, Clostridium, compared to ethnicity-matched controls.

41 species within Lactobacillus, Streptococcus, Clostridium, Desulfovibrio, Enterococcus, Fusobacterium,

42 tracheostomy (21.6% vs 4.5%), development of Clostridium difficile (4.5% vs 1.7%), and incidence dens

43 gens detected by the FilmArray GI panel were Clostridium difficile (55.0%), Campylobacter species (20

44 agents also increase the risk of developing Clostridium difficile (also known as Clostridioides diff

45 Clostridium difficile (C. difficile) incidence has tripl

46 All samples positive for Clostridium difficile (CD) and its toxin were considered

47 lt from a polymerase chain reaction test for Clostridium difficile (CD) toxin 8 weeks after the alloc

48 The major global pathogen Clostridium difficile (recently renamed Clostridioides d

49 xin (CTB5) and a subfragment of toxin A from Clostridium difficile (TcdA-A2).

50 TcdB) are produced by the bacterial pathogen Clostridium difficile and are responsible for the pathol

51 outcomes of hospitalized patients tested for Clostridium difficile and determine the correlation betw

52 fections of Gram-positive bacteria including Clostridium difficile and methicillin-resistant Staphylo

53 microbiota of gnotobiotic mice infected with Clostridium difficile and the core microbiota of the sea

54 applies to the CD27L endolysin that targets Clostridium difficile and the CS74L endolysin that targe

55 ssociation of proton pump inhibitor use with Clostridium difficile and ventilator-associated pneumoni

56 Infections with Clostridium difficile are a health threat, yet no produc

57 Nosocomial infections with Clostridium difficile are on the rise in the Unites Stat

58 Clostridium difficile causes toxin-mediated nosocomial d

59 perative pneumonia, urinary tract infection, Clostridium difficile colitis, sepsis, or death.

60 Patients with differential diagnosis (Clostridium difficile colitis, viral colitis, inflammato

61 istula, stricture/obstruction, and fulminant Clostridium difficile colitis.

62 ng of the role of patients with asymptomatic Clostridium difficile colonization in transmission.

63 The diarrheal pathogen Clostridium difficile consists of at least six distinct

64 There is no stand-alone Clostridium difficile diagnostic that can sensitively an

65 an acquire multidrug-resistant organisms and Clostridium difficile from inadequately disinfected envi

66 eliable tools for the detection of toxigenic Clostridium difficile from unformed (liquid or soft) sto

67 Clostridium difficile has become one of the most common

68 Clostridium difficile has emerged as a noteworthy pathog

69 Unlike in B. subtilis, SpoIIQ of Clostridium difficile has intact LytM zinc-binding motif

70 Drivers of differences in Clostridium difficile incidence across acute and long-te

71 were rated >6 in all criteria: 2 measures of Clostridium difficile incidence, incidence of drug-resis

72 plification tests (NAATs) do not distinguish Clostridium difficile infection (CDI) and asymptomatic C

73 Isolates obtained from patients with Clostridium difficile infection (CDI) and colonization i

74 s of Staphylococcus aureus bacteremia (SAB), Clostridium difficile infection (CDI) and vancomycin-res

75 Candidemia and Clostridium difficile infection (CDI) are important heal

76 es suggest that most cases of hospital-onset Clostridium difficile infection (CDI) are unrelated to o

77 Little is known about pediatric Clostridium difficile infection (CDI) epidemiology.

78 dies on risk factors for and transmission of Clostridium difficile infection (CDI) in China have been

79 ) is highly effective for treating recurrent Clostridium difficile infection (CDI) in observational s

80 e an appropriate therapeutic option for mild Clostridium difficile infection (CDI) in select patients

81 Clostridium difficile infection (CDI) is a frequent comp

82 Clostridium difficile infection (CDI) is a leading cause

83 Clostridium difficile infection (CDI) is a major nosocom

84 Clostridium difficile infection (CDI) is an important ho

85 Clostridium difficile infection (CDI) is facilitated by

86 Clostridium difficile infection (CDI) is mediated by act

87 Clostridium difficile infection (CDI) is mediated by two

88 Clostridium difficile infection (CDI) is the leading cau

89 Clostridium difficile infection (CDI) is the number one

90 Managing recurrent Clostridium difficile infection (CDI) presents a signifi

91 Variation in Clostridium difficile infection (CDI) rates between heal

92 rganism bloodstream infection (MDRO-BSI) and Clostridium difficile infection (CDI) rates in the 12 mo

93 Clostridium difficile infection (CDI) represents an impo

94 crobiota transplant (FMT) is recommended for Clostridium difficile infection (CDI) treatment; however

95 for the efficacy of probiotics in preventing Clostridium difficile infection (CDI), but guidelines do

96 (FT) is a promising treatment for recurrent Clostridium difficile infection (CDI), but its true effe

97 Clostridium difficile infection (CDI), the most common h

98 ens, including acute kidney injury (AKI) and Clostridium difficile infection (CDI), were also conside

99 nts, including acute kidney injury (AKI) and Clostridium difficile infection (CDI).

100 peutic effects of dietary supplementation on Clostridium difficile infection (CDI).

101 considered important for protection against Clostridium difficile infection (CDI).

102 is a highly effective therapy for recurrent Clostridium difficile infection (CDI).

103 -Counterpoint on the laboratory diagnosis of Clostridium difficile infection (CDI).

104 rope and the United States for patients with Clostridium difficile infection (CDI).

105 an transplantation (Tx) is a risk factor for Clostridium difficile infection (CDI).

106 h care-onset health care facility-associated Clostridium difficile infection (HO-CDI) is overdiagnose

107 actam (PIP/TAZO) shortage and hospital-onset Clostridium difficile infection (HO-CDI) risk in 88 US m

108 T) is recommended for treatment of recurrent Clostridium difficile infection (rCDI).

109 Clostridium difficile infection after LT was associated

110 Clostridium difficile infection causes severe complicati

111 The gut microbiota in recurrent Clostridium difficile infection had lower density and re

112 The incidence of Clostridium difficile infection has increased among chil

113 Colitis caused by Clostridium difficile infection is a growing cause of hu

114 Clostridium difficile infection is a growing problem in

115 Targeting Clostridium difficile infection is challenging because t

116 Clostridium difficile infection is the leading cause of

117 Clostridium difficile infection is the most common healt

118 reports found addressed the use of FMTs for Clostridium difficile infection or inflammatory bowel di

119 dmission rates, central venous catheter use, Clostridium difficile infection rates, and hospital leng

120 8, P = 0.04, I = 36%), with no difference in Clostridium difficile infection rates.

121 e-level association test of the reduction in Clostridium difficile infection recurrence in patients t

122 Whereas many antibiotics increase risk of Clostridium difficile infection through dysbiosis, epide

123 cohort of 109 subjects treated for recurrent Clostridium difficile infection with fecal microbiota tr

124 with outcomes (antibiotic-days, incidence of Clostridium difficile infection, and in-hospital mortali

125 numbers of Staphylococcus aureus bacteremia, Clostridium difficile infection, and vancomycin-resistan

126 py, and frequency of complications including Clostridium difficile infection, readmission, and all-ca

127 acious and inexpensive therapy for recurrent Clostridium difficile infection, yet its safety is thoug

128 rectal procedures without increased risk of Clostridium difficile infection.

129 a transplantation for treatment of recurrent Clostridium difficile infection.

130 idity, development of ileus, reoperation and Clostridium difficile infection.

131 xolidinone antibiotic developed for treating Clostridium difficile infection.

132 nsecutive, evaluable patients with recurrent Clostridium difficile infection.

133 and fidaxomicin are therapies of choice for Clostridium difficile infection.

134 ns about promoting antibiotic resistance and Clostridium difficile infection.

135 Community-onset Clostridium difficile infections (CDI) are increasingly

136 ic, is an investigational drug indicated for Clostridium difficile infections (CDI).

137 BACKGROUND & AIMS: Studies of Clostridium difficile infections (CDIs) among individual

138 Clostridium difficile infections (CDIs) are a growing he

139 d dysbiosis is a key predisposing factor for Clostridium difficile infections (CDIs), which cause int

140 al microbiota transplantation to face severe Clostridium difficile infections and to perform decoloni

141 n-resistant Staphylococcus aureus (MRSA) and Clostridium difficile infections declined across the UK

142 biotic-based strategies for the treatment of Clostridium difficile infections disrupt indigenous micr

143 The control of Clostridium difficile infections is an international cli

144 as oral non-systemic antibacterial drugs for Clostridium difficile infections were active against pat

145 han 9000 nosocomial infections, 1000 to 5000 Clostridium difficile infections, and 2 to 6 cases of an

146 Clostridium difficile is a clinically significant pathog

147 Clostridium difficile is a gastrointestinal pathogen but

148 Clostridium difficile is a Gram-positive bacterium with

149 Clostridium difficile is a major nosocomial pathogen tha

150 Clostridium difficile is a significant concern as a noso

151 Clostridium difficile is a significant pathogen in healt

152 orming, healthcare-associated enteropathogen Clostridium difficile is actively undergoing speciation.

153 Clostridium difficile is an anaerobic and spore-forming

154 Clostridium difficile is an opportunistic pathogen that

155 ecal toxin negative (FT-) in transmission of Clostridium difficile is currently unknown.

156 Clostridium difficile is the cause of antibiotics-associ

157 Clostridium difficile is the most commonly reported noso

158 Clostridium difficile is the most important enteropathog

159 Although Clostridium difficile is widely considered an antibiotic

160 ed in colonic neurons of human patients with Clostridium difficile or ulcerative colitis.

161 nhancing probiotic bacteria activity against Clostridium difficile pathogenesis in vivo.

162 tem cell regeneration and, more recently, in Clostridium difficile pathogenesis.

163 Clostridium difficile PCR ribotype 265 (toxin A negative

164 ACKGROUND & AIMS: Nosocomial infections with Clostridium difficile present a considerable problem des

165 Clostridium difficile TcdB (2366 amino acid residues) is

166 metalloprotease from the bacterial pathogen Clostridium difficile that cleaves two endogenous adhesi

167 n that we identified from the human pathogen Clostridium difficile The crystal structure shows that t

168 Clostridium difficile toxin A (TcdA) is a major exotoxin

169 response to Rho-modifying toxins, including Clostridium difficile toxins A and B.

170 ient stools, it detected the toxin B gene of Clostridium difficile with 95% sensitivity and 95% speci

171 500 muM and are known to block the growth of Clostridium difficile(1), promote hepatocellular carcino

172 inococcus obeum, Salmonella typhimurium, and Clostridium difficile) to quantify, expand, and characte

173 cy, or benign disease (diverticular disease, Clostridium difficile) undergoing major abdominal surger

174 The glucosyltransferase TcdB from Clostridium difficile, a well-studied RhoA-inactivating

175 aphylococcus aureus, Pseudomonas aeruginosa, Clostridium difficile, and fungal infections) in pediatr

176 rio cholerae, the hydrosulphide channel from Clostridium difficile, and the uncharacterized channel f

177 In the intestinal pathogen Clostridium difficile, c-di-GMP inhibits flagellar motil

178 s that are not reported at this institution (Clostridium difficile, enteroaggregative Escherichia col

179 ts to the health service and predisposing to Clostridium difficile, methicillin-resistant Staphylococ

180 pansion of several potential pathogens (e.g. Clostridium difficile, Salmonella, and Escherichia coli)

181 ansplantation led to resolution of recurrent Clostridium difficile, significantly decreased recurrent

182 Clostridium difficile, the causal agent of antibiotic-as

183 Unlike other bacteria, Clostridium difficile, the major human pathogen responsi

184 ared to those of mapping-based approaches in Clostridium difficile, using repeated sequencing of the

185 Clostridium difficile-associated diarrhea (CDAD) is comm

186 a, Eggerthella, and the potential pathobiont Clostridium difficile.

187 fluence susceptibility to pathogens, such as Clostridium difficile.

188 re-forming pathogens, Bacillus anthracis and Clostridium difficile.

189 Clostridioides difficile (formerly Clostridium difficile; C difficile), the leading cause o

190 Clostridioides (Clostridium) difficile colonization is common among infa

191 trum antibiotic approved for Clostridioides (Clostridium) difficile infection (CDI) in adults, is ass

192 Clostridioides (formerly Clostridium) difficile infection (CDI) is associated wit

193 is and treatment of Clostridioides (formerly Clostridium) difficile infection (CDI).

194 riptions) ADRs, with Clostridiodes (formerly Clostridium) difficile infections pivotal to its ADR pro

195 Clostridioides (formerly Clostridium) difficile is a Gram-positive, spore-forming

196 Clostridioides (formerly Clostridium) difficile is a leading cause of healthcare-

197 Clostridioides (formerly known as Clostridium) difficile is the leading cause of hospital-

198 Clostridioides (formerly Clostridium) difficile is the most common cause of hospi

199 r concentrations of Clostridioides (formerly Clostridium) difficile toxins A and/or B in the stool of

200 us antibodies (eAbs) against Clostridioides (Clostridium) difficile toxins may protect against recurr

201 In mattress dust, the genera Clostridium, Facklamia, an unclassified genus within the

202 ly Victivallaceae, and genera Cetobacterium, Clostridium, Faecalibacterium, Lachnospira, Paraprevotel

203 Bacteria of the genera Bacillus and Clostridium form highly resistant spores, which in the c

204 Chath_Est1 from the anaerobic risk 1 strain Clostridium hathewayi DSM-13479 was found to hydrolyze P

205 lesional therapies, particularly collagenase clostridium histolyticum (CCH), have shown promise.

206 t Pseudomonas aeruginosa elastase (LasB) and Clostridium histolyticum (Hathewaya histolytica) collage

207 collagenase H (ColH) from the human pathogen Clostridium histolyticum.

208 both the Bacteroides-Prevotella spp. and the Clostridium-histolyticum groups, and increased the short

209 microbial culture techniques, we discovered Clostridium immunis, a previously unknown bacterial spec

210 CD ileal surgical resections, and identified Clostridium innocuum as a signature of this consortium w

211 heat-treated anaerobic digester sludge with Clostridium kluyveri (AS + Ck) on caproic acid productio

212 accompanied with the decreased abundance of Clostridium, Lactobacillus, Desulfovibrio, and Methyloba

213 Clostridium ljungdahlii derives energy by lithotrophic a

214 ights into the biology of the model acetogen Clostridium ljungdahlii.

215 , Dorea (log2 fold change -1.65, P=.02), and Clostridium (log2 fold change -1.47, P=.002) were underr

216 nd 78 controls showed an association between Clostridium neonatale and Staphylococcus aureus with NEC

217 coccus faecalis, Lactobacillus crispatus and Clostridium orbiscindens) promote resistance to lung inf

218 A specific human-associated gut microbe, Clostridium orbiscindens, produced DAT and rescued antib

219 of LNS on growth appeared to be modified by Clostridium (p-for-interaction = 0.02), Ruminococcus (p-

220 Using the [FeFe]-hydrogenases from Clostridium pasteurianum (CpI) and Chlamydomonas reinhar

221 From a library of 10 080 randomly mutated Clostridium pasteurianum [FeFe] hydrogenases, we found a

222 The microbe Clostridium pasteurianum produces three [FeFe]-hydrogena

223 crystals of the [FeFe]-hydrogenase CpI from Clostridium pasteurianum to oxygen and quantitatively in

224 mutagenesis in the [FeFe]-hydrogenase CpI of Clostridium pasteurianum to reveal the final steps of H-

225 itrogenases (Azotobacter vinelandii, Av, and Clostridium pasteurianum, Cp) at pHs between 4.5 and 8.

226 An [FeFe]-hydrogenase from Clostridium pasteurianum, CpI, is a model system for bio

227 ux pump gene (acr3) in one of the anaerobes, Clostridium pasteurianum, rendered the strain sensitive

228 ter," and CpI from the fermentative anaerobe Clostridium pasteurianum, which contains four low-potent

229 e microbial community was dominated (19%) by Clostridium pasteurianum.

230 provide evidence that production of the anti-Clostridium peptide RumC depends on an R. gnavus operon

231 Comparison of product binding with BSH from Clostridium perfringenes reveals a distinct orientation

232 against pathogenic bacterial sialidases from Clostridium perfringens (CpNanI) and Vibrio cholerae.

233 caused by gas- forming bacteria - most often Clostridium perfringens and Escherichia coli.

234 ization and replication of bacteria, such as Clostridium perfringens and Salmonella enterica serovar

235 show that Clostridium perfringens beta-toxin (CPB) binds platelet

236 h potent activity against the human pathogen Clostridium perfringens By combining in vivo and in vitr

237 Clostridium perfringens can produce up to three differen

238 Clostridium perfringens enterotoxin (CPE) causes food po

239 Clostridium perfringens enterotoxin (CPE) is a pore-form

240 A published complex of Clostridium perfringens GH125 enzyme with a nonhydrolyza

241 Necrotic enteritis (NE) caused by Clostridium perfringens infection has reemerged as a pre

242 Clostridium perfringens is a leading cause of food-poiso

243 Necrotic enteritis (NE) caused by Clostridium perfringens is one of the most detrimental i

244 ysis, we were able to identify inhibitors of Clostridium perfringens neuraminidase present in a root

245 The human pathogenic bacterium Clostridium perfringens secretes an enterotoxin (CpE) th

246 Many Clostridium perfringens strains produce NanI as their ma

247 2-aminobenzoic acid using neuraminidase from Clostridium perfringens that cleaves sialic acid monomer

248 Clostridium perfringens type D strains cause enterotoxem

249 ubnetworks associated with responses against Clostridium perfringens, Candida albicans, and Bacteroid

250 c properties against human pathogens such as Clostridium perfringens, define two hairpin domains givi

251 d (Staphylococcus aureus, Bacillus subtilis, Clostridium perfringens, Escherichia coli), except Enter

252 potent pore forming toxin (PFT) produced by Clostridium perfringens, is responsible for the pathogen

253 reduced disease-associated bacteria such as Clostridium perfringens, Ruminococcus gnavus, and Klebsi

254 ell walls by the cellulolytic soil bacterium Clostridium phytofermentans produces toxic aldehyde inte

255 e encoded in the genome of the novel species Clostridium porci, and prevalent gene clusters for biosy

256 Clostridium (Ruminiclostridium) thermocellum is recogniz

257 ncanonical, functional LsrB-type receptor in Clostridium saccharobutylicum.

258 g pro-androgen formation in bacteria such as Clostridium scindens and 21-dehydroxylation by Eggerthel

259 primary bile acids in in vitro assays, and a Clostridium scindens strain produces secondary bile acid

260 onstitution with a single bacterial species, Clostridium scindens, or its derived metabolite, the sec

261 tabolism and specific microbiota, especially Clostridium scindens.

262 In ileal samples, the genus Clostridium sensu stricto was dramatically reduced in th

263 h the development of colon tumors, including Clostridium septicum, and decreased amounts of beneficia

264 r CDC family members, and the alpha-toxin of Clostridium septicum, which generates pores with cross-s

265 major virulence factor in Paeniclostridium (Clostridium) sordellii and responsible for the high leth

266 howed enrichment and increased prevalence of Clostridium species and a depletion of, for example, Eub

267 t progress towards engineering solventogenic Clostridium species that are tolerant to lignocellulosic

268 dhere to epithelial cells as well as several Clostridium species, can alter differentiation of T help

269 ng a remarkable predominance of Serratia and Clostridium species, which switched from asymptomatic gu

270 n in other spore forming bacteria, including Clostridium species.

271 Additionally, we demonstrated that Clostridium sporogenes decreased the activity of both C.

272 iavidus metallidurans, Escherichia coli, and Clostridium sporogenes species were chosen for their red

273 characterize a pathway from the gut symbiont Clostridium sporogenes that generates aromatic amino aci

274 the structures of the stator complexes from Clostridium sporogenes, Bacillus subtilis and Vibrio mim

275 We then engineer the pathway into Clostridium sporogenes, conferring production of DCA and

276 this method to the model commensal organism Clostridium sporogenes, we knocked out genes for 10 C. s

277 fficile and the CS74L endolysin that targets Clostridium sporogenes.

278 Clostridium spp., Bacteroides uniformis, Christensenella

279 a system for constructing clean deletions in Clostridium spp., the source of many molecules from the

280 ed 4 SCFA-producers (Bifidobacterium longum, Clostridium symbiosum, Faecalibacterium prausnitzii, and

281 wo invasive species, Ruminococcus gnavus and Clostridium symbiosum, to the microbiota from undernouri

282 ease is caused by the toxin of the bacterium Clostridium tetani and is characterised by muscle spasms

283 iously the crystal structures of a PCAT from Clostridium thermocellum (PCAT1) were determined in the

284 he sactionine bond-forming enzyme CteB, from Clostridium thermocellum ATCC 27405, with both SAM and a

285 We report here that Clostridium thermocellum can solubilize over 90% of the

286 Clostridium thermocellum could potentially be used as a

287 )-PFKs of Clostridium thermosuccinogenes and Clostridium thermocellum indeed can convert S7P to SBP,

288 Clostridium thermocellum is a good candidate organism fo

289 s in BiFae1B with the feruloyl esterase from Clostridium thermocellum suggest that both domains lack

290 hieved by the method on Escherichia coli and Clostridium thermocellum, substantial work is needed to

291 We show that PP(i)-PFKs of Clostridium thermosuccinogenes and Clostridium thermocel

292 Clostridium tyrobutyricum, Veillonella criceti, or Megas

293 etate oxidizers Syntrophaceticus schinkii, [ Clostridium] ultunense, and Tepidanaerobacter acetatoxyd

294 g Turicibacter, Akkermansia, Prevotella, and Clostridium Using a correlation network modeling approac

295 abundance of Oscillospira and a decrease in Clostridium, which seem to be associated with lower leve

296 ile significantly decreased the abundance of Clostridium XI.

297 33.6, 591; P = 0.04), and lower abundance of Clostridium XIVa (Q4-Q1: beta: -41.1; 95% CI: -72.4, -9.

298 on with a bloom in Akkermansia and increased Clostridium XIVa genera, whose abundance was positively

299 and Ruminococcaceae, and lower abundance of Clostridium XIVa had lower amounts of VAT.

300 of Escherichia/Shigella, Butyricicoccus, and Clostridium XlVa, while significantly decreased the abun